Coronavirus disease 2019 (COVID-19) vaccines effectively elicit humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in healthy populations. This immunity decreases several months after vaccination. However, the efficacy of vaccine-induced immunity and its durability in patients with severe asthma on biological therapy are unknown. In this study, we evaluated the effectiveness and durability of mRNA vaccine-induced SARS-CoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy. The study included 34 patients with severe asthma treated with anti-IgE (omalizumab, n=17), anti-IL5 (mepolizumab, n=13; reslizumab, n=3), or anti-IL5R (benralizumab, n=1) biological therapy. All patients were vaccinated with two doses of the BNT162b2 mRNA vaccine with a 6-week interval between the doses. We found that this COVID-19 vaccination regimen elicited SARS-CoV-2-specific humoral and cellular immunity, which had significantly declined 6 months after receipt of the second dose of the vaccine. The type of biological treatment did not affect vaccine-elicited immunity. However, patient age negatively impacted the vaccine-induced humoral response. On the other hand, no such age-related impact on vaccine-elicited cellular immunity was observed. Our findings show that treatment of patients with severe asthma with biological therapy does not compromise the effectiveness or durability of COVID-19 vaccine-induced immunity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163958 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.892277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Since the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the need for an effective vaccine has appeared crucial for stimulating immune system responses to produce humoral/cellular immunity and activate immunological memory. It has been demonstrated that SARS-CoV-2 variants escape neutralizing immunity elicited by previous infection and/or vaccination, leading to new infection waves and cases of reinfection. The study aims to gain into cases of reinfections, particularly infections and/or vaccination-induced protection.
View Article and Find Full Text PDFEndoVIA for quantifying A-to-I editing and mapping the subcellular localization of edited transcripts.
Methods Enzymol
January 2025
Department of Chemistry, Washington University in St. Louis, MO, United States. Electronic address:
Adenosine-to-inosine (A-to-I) editing, catalyzed by adenosine deaminases acting on RNA (ADARs), is a prevalent post-transcriptional modification that is vital for numerous biological functions. Given that this modification impacts global gene expression, RNA localization, and innate cellular immunity, dysregulation of A-to-I editing has unsurprisingly been linked to a variety of cancers and other diseases. However, our current understanding of the underpinning mechanisms that connect dysregulated A-to-I editing and disease processes remains limited.
View Article and Find Full Text PDFStructural analysis of human ADAR2-RNA complexes by X-ray crystallography.
Methods Enzymol
January 2025
Department of Chemistry, University of California, Davis, CA, United States; Department of Molecular and Cellular Biology, University of California, Davis, CA, United States. Electronic address:
Adenosine deaminases acting on RNAs (ADARs) are a class of RNA editing enzymes found in metazoa that catalyze the hydrolytic deamination of adenosine to inosine in duplexed RNA. Inosine is a nucleotide that can base pair with cytidine, therefore, inosine is interpreted by cellular processes as guanosine. ADARs are functionally important in RNA recoding events, RNA structure modulation, innate immunity, and can be harnessed for therapeutically-driven base editing to treat genetic disorders.
View Article and Find Full Text PDFHow short-term change in temperature or salinity affect cellular immune parameters of three-spined stickleback, Gasterosteus aculeatus?
Mar Environ Res
January 2025
Institut national de l'environnement industriel et des risques, Université de Reims Champagne-Ardenne, Université Le Havre Normandie, Normandie Univ, UMR-I 02 SEBIO, 60550, Verneuil-en-Halatte, France.
Reference values for the non-specific immune response of stickleback have been developed to better understand the natural variability of the immunomarkers and to increase their relevance for the detection of environmental perturbations. However, under field conditions, temperature and salinity can vary from station to station and their influence on the reference ranges of the immunomarkers should therefore be quantified. To this end, adult sticklebacks were exposed either to different temperatures (from 12 to 18 °C) or to different salinities (from 0 to 30 g/L) for 21 days after 10 days of acclimatization.
View Article and Find Full Text PDFSpectrum and trends of cancer among HIV patients in Southwestern Uganda.
PLoS One
January 2025
Department of Microbiology, Mbarara University of Science and Technology, Uganda.
Background: Antiretroviral therapy (ART) restores cellular immunity, significantly reducing AIDS-related mortality and morbidity thus improving the quality of life among People living with HIV (PLHIV). Studies done in several countries show a decline in AIDS defining cancers (ADCs) with the introduction of ART however the increased longevity has led to the increase of Non-AIDS defining cancers (NADCs). The study was aimed at studying the changing spectrum and trends of cancer among Human Immunodeficiency Virus (HIV) patients in southwestern Uganda.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!